{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,4]],"date-time":"2026-08-04T20:46:25Z","timestamp":1785876385444,"version":"3.56.0"},"reference-count":23,"publisher":"Elsevier BV","issue":"7","license":[{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,4,14]],"date-time":"2026-04-14T00:00:00Z","timestamp":1776124800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100020483","name":"Insmed Incorporated","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100020483","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","clinicaltherapeutics.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Therapeutics"],"published-print":{"date-parts":[[2026,7]]},"DOI":"10.1016\/j.clinthera.2026.04.007","type":"journal-article","created":{"date-parts":[[2026,5,15]],"date-time":"2026-05-15T21:21:08Z","timestamp":1778880068000},"page":"610-614","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["A Simultaneous Assessment of Efficacy and Safety of Amikacin Liposome Inhalation Suspension for Refractory Mycobacterium avium Complex Lung Disease"],"prefix":"10.1016","volume":"48","author":[{"given":"Daniel","family":"Dorgan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Catherine","family":"Waweru","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kim","family":"Cocks","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rachael","family":"Lawrance","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthias","family":"Hunger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ankit","family":"Pahwa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dayton W.","family":"Yuen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Leona E.","family":"Markson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.clinthera.2026.04.007_bib0001","doi-asserted-by":"crossref","first-page":"982","DOI":"10.1016\/j.chest.2016.10.055","article-title":"Adult patients with bronchiectasis: a first look at the US Bronchiectasis Research Registry","volume":"151","author":"Aksamit","year":"2017","journal-title":"Chest"},{"key":"10.1016\/j.clinthera.2026.04.007_bib0002","doi-asserted-by":"crossref","first-page":"1120","DOI":"10.1513\/AnnalsATS.201610-801OC","article-title":"Long-term outcomes in a population-based cohort with respiratory nontuberculous mycobacteria isolation","volume":"14","author":"Henkle","year":"2017","journal-title":"Ann Am Thorac Soc"},{"key":"10.1016\/j.clinthera.2026.04.007_bib0003","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1016\/j.ccm.2014.10.002","article-title":"Epidemiology of human pulmonary infection with nontuberculous mycobacteria: a review","volume":"36","author":"Prevots","year":"2015","journal-title":"Clin Chest Med"},{"key":"10.1016\/j.clinthera.2026.04.007_bib0004","doi-asserted-by":"crossref","first-page":"905","DOI":"10.1093\/cid\/ciaa1125","article-title":"Treatment of nontuberculous mycobacterial pulmonary disease: an official ATS\/ERS\/ESCMID\/IDSA clinical practice guideline","volume":"71","author":"Daley","year":"2020","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.clinthera.2026.04.007_bib0005","doi-asserted-by":"crossref","first-page":"888","DOI":"10.1016\/j.chest.2018.01.024","article-title":"Microbiologic outcome of interventions against","volume":"153","author":"Diel","year":"2018","journal-title":"Chest"},{"key":"10.1016\/j.clinthera.2026.04.007_bib0006","doi-asserted-by":"crossref","DOI":"10.1016\/j.rmed.2025.108220","article-title":"Natural history and burden of refractory Mycobacterium avium complex pulmonary disease: insights from the US Bronchiectasis and Nontuberculous Mycobacterial Research Registry","volume":"246","author":"Aksamit","year":"2025","journal-title":"Respir Med"},{"key":"10.1016\/j.clinthera.2026.04.007_bib0007","doi-asserted-by":"crossref","first-page":"700","DOI":"10.1186\/s12913-018-3489-8","article-title":"The cost of Mycobacterium avium complex lung disease in Canada, France, Germany, and the United Kingdom: a nationally representative observational study","volume":"18","author":"Goring","year":"2018","journal-title":"BMC Health Serv Res"},{"key":"10.1016\/j.clinthera.2026.04.007_bib0008","unstructured":"Arikayce. Prescribing information. Insmed; 2025. Accessed March 10, 2025. https:\/\/www.arikayce.com\/pdf\/full_prescribing_information.pdf."},{"key":"10.1016\/j.clinthera.2026.04.007_bib0009","doi-asserted-by":"crossref","first-page":"1559","DOI":"10.1164\/rccm.201807-1318OC","article-title":"Amikacin liposome inhalation suspension for treatment-refractory lung disease caused by Mycobacterium avium complex (CONVERT). A prospective, open-label, randomized study","volume":"198","author":"Griffith","year":"2018","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.clinthera.2026.04.007_bib0010","doi-asserted-by":"crossref","first-page":"1772","DOI":"10.1200\/JCO.1986.4.12.1772","article-title":"A new endpoint for the assessment of adjuvant therapy in postmenopausal women with operable breast cancer","volume":"4","author":"Gelber","year":"1986","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.clinthera.2026.04.007_bib0011","doi-asserted-by":"crossref","first-page":"961","DOI":"10.7326\/0003-4819-116-12-961","article-title":"Quality-of-life evaluation in a clinical trial of zidovudine therapy in patients with mildly symptomatic HIV infection. The AIDS Clinical Trials Group","volume":"116","author":"Gelber","year":"1992","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.clinthera.2026.04.007_bib0012","doi-asserted-by":"crossref","first-page":"754","DOI":"10.1001\/archneur.1995.00540320026010","article-title":"Measuring patient-centered outcomes in neurologic disease. Extending the Q-TWiST method","volume":"52","author":"Schwartz","year":"1995","journal-title":"Arch Neurol"},{"key":"10.1016\/j.clinthera.2026.04.007_bib0013","doi-asserted-by":"crossref","first-page":"00057","DOI":"10.1183\/23120541.00057-2023","article-title":"Efficacy and safety of oral corticosteroids to treat outpatients with acute exacerbations of COPD in primary care: a multicentre pragmatic randomised controlled study","volume":"9","author":"Thebault","year":"2023","journal-title":"ERJ Open Res"},{"key":"10.1016\/j.clinthera.2026.04.007_bib0014","doi-asserted-by":"crossref","first-page":"1587","DOI":"10.1038\/bjc.2012.149","article-title":"Q-TWiST analysis to estimate overall benefit for patients with metastatic renal cell carcinoma treated in a phase III trial of sunitinib","volume":"106","author":"Patil","year":"2012","journal-title":"Br J Cancer"},{"key":"10.1016\/j.clinthera.2026.04.007_bib0015","unstructured":"National Cancer Institute Division of Cancer Treatment & Diagnosis. CTCAE and adverse event reporting. National Cancer Institute; 2025. Accessed March 10, 2025. https:\/\/dctd.cancer.gov\/research\/ctep-trials\/for-sites\/adverse-events."},{"key":"10.1016\/j.clinthera.2026.04.007_bib0016","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1007\/s41030-024-00263-1","article-title":"Qualitative interviews exploring adverse event mitigation strategies in adults receiving amikacin liposome inhalation suspension","volume":"10","author":"Ali","year":"2024","journal-title":"Pulm Ther"},{"key":"10.1016\/j.clinthera.2026.04.007_bib0017","doi-asserted-by":"crossref","first-page":"ofaa079","DOI":"10.1093\/ofid\/ofaa079","article-title":"Clinical management of respiratory adverse events associated with amikacin liposome inhalation suspension: results from a patient survey","volume":"7","author":"Swenson","year":"2020","journal-title":"Open Forum Infect Dis"},{"key":"10.1016\/j.clinthera.2026.04.007_bib0018","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1186\/s12890-022-02257-8","article-title":"Impact of initiation of amikacin liposome inhalation suspension on hospitalizations and other healthcare resource utilization measures: a retrospective cohort study in real-world settings","volume":"22","author":"Aksamit","year":"2022","journal-title":"BMC Pulm Med"},{"key":"10.1016\/j.clinthera.2026.04.007_bib0019","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1007\/s41030-025-00324-z","article-title":"Healthcare resource utilization in refractory MACLD: comparison of an amikacin liposome inhalation suspension (ALIS) cohort with a non-ALIS cohort","volume":"12","author":"Aksamit","year":"2026","journal-title":"Pulm Ther"},{"key":"10.1016\/j.clinthera.2026.04.007_bib0020","doi-asserted-by":"crossref","DOI":"10.1016\/j.rmed.2025.108406","article-title":"Persistent use of amikacin liposome inhalation suspension associated with lower risk of hospitalizations and emergency room visits in refractory","volume":"249","author":"Winthrop","year":"2025","journal-title":"Respir Med"},{"key":"10.1016\/j.clinthera.2026.04.007_bib0021","doi-asserted-by":"crossref","first-page":"781","DOI":"10.2307\/2531683","article-title":"A quality-of-life-oriented endpoint for comparing therapies","volume":"45","author":"Gelber","year":"1989","journal-title":"Biometrics"},{"key":"10.1016\/j.clinthera.2026.04.007_bib0022","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1007\/s11136-005-1579-7","article-title":"Analyzing oncology clinical trial data using the Q-TWiST method: clinical importance and sources for health state preference data","volume":"15","author":"Revicki","year":"2006","journal-title":"Qual Life Res"},{"key":"10.1016\/j.clinthera.2026.04.007_bib0023","doi-asserted-by":"crossref","first-page":"1108","DOI":"10.1016\/j.chest.2023.06.015","article-title":"Microbiological cure at treatment completion is associated with longer survival in patients with","volume":"164","author":"Kim","year":"2023","journal-title":"Chest"}],"container-title":["Clinical Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0149291826001116?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0149291826001116?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,8,4]],"date-time":"2026-08-04T20:05:36Z","timestamp":1785873936000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0149291826001116"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7]]},"references-count":23,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2026,7]]}},"alternative-id":["S0149291826001116"],"URL":"https:\/\/doi.org\/10.1016\/j.clinthera.2026.04.007","relation":{},"ISSN":["0149-2918"],"issn-type":[{"value":"0149-2918","type":"print"}],"subject":[],"published":{"date-parts":[[2026,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"A Simultaneous Assessment of Efficacy and Safety of Amikacin Liposome Inhalation Suspension for Refractory Mycobacterium avium Complex Lung Disease","name":"articletitle","label":"Article Title"},{"value":"Clinical Therapeutics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clinthera.2026.04.007","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Author(s). Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}